Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Proteobacteria is the largest and most diverse phylum of Gram-negative bacteria, encompassing a broad range of ecological and medical significance. The group is subdivided into six classes: Alphaproteobacteria, Betaproteobacteria, Gammaproteobacteria, Deltaproteobacteria, Epsilonproteobacteria, and Zetaproteobacteria. Members range from important human and animal pathogens (Escherichia coli, Salmonella, Neisseria, Helicobacter, Vibrio) and plant symbionts (Rhizobium) to environmental bacteria involved in nitrogen and sulfur cycling. The common feature across Proteobacteria is their Gram-negative cell envelope structure, but otherwise they display extensive metabolic and ecological diversity. The term was established based on 16S rRNA gene phylogeny.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Proteobacteria.